Eli Lilly's QWINT-2 And QWINT-4 Phase 3 Trials Of Once-weekly Insulin Efsitora In Type 2 Diabetes Patients Using Insulin For First Time And Require Multiple Daily Injections, Efsitora Showed Non-Inferior A1C Reduction Vs. Most Commonly Used Daily ...

+1.80%

Eli Lilly and Company

LLY

1027.51

+1.80%

Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes
Efsitora was equally safe and effective among adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.